Search
Calcium glubionate anhydrous
go.drugbank.com/drugs/DB13142ApprovedCalcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Almasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer.
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
Aprotinin
go.drugbank.com/drugs/DB06692ApprovedInvestigationalWithdrawnAprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). … The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery.
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.
Pentetreotide
go.drugbank.com/drugs/DB12602ApprovedWithdrawnPentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Categories: Compounds used in a research, industrial, or household settingPotassium bitartrate
go.drugbank.com/drugs/DB11107ApprovedInvestigationalPotassium bitartrate has a long history of medical use as a laxative administered as a rectal suppository and is an approved third-class OTC drug in Japan. … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]
Erlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalRecent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexPlasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigational[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … [A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer.